| 24 | 1/1 | 返回列表 |
| 查看: 1002 | 回復(fù): 23 | |||||||||
| 【有獎交流】積極回復(fù)本帖子,參與交流,就有機會分得作者 smhwayne 的 27 個金幣 ,回帖就立即獲得 1 個金幣,每人有 1 次機會 | |||||||||
[交流]
韋恩州立大學(xué)及 Karmanos 癌癥研究所誠招博士后
|
|||||||||
研究方向: 腫瘤微環(huán)境;腫瘤轉(zhuǎn)移;免疫治療及耐藥性 起始時間: 2022年3月左右 (具體時間可協(xié)商) 應(yīng)聘要求: 具有生物醫(yī)學(xué)/腫瘤學(xué)/分子生物學(xué) 或者相關(guān)領(lǐng)域的博士學(xué)位。在生物信息學(xué),腫瘤生物學(xué),細胞生物學(xué),或者免疫學(xué)相關(guān)領(lǐng)域有一作文章者優(yōu)先。最好有一定的動物(小鼠)實驗操作背景。有良好的英語寫作和溝通能力。 有意向者請將英文自薦信(篇幅小于一頁)和英文簡歷發(fā)送到 minhong.shen@wayne.edu 或 minhongshen86@gmail.com 簡介: Postdoctoral positions are available for highly motivated candidates in Dr. Minhong Shen Lab at the Department of Pharmacology and Oncology, Wayne State University School of Medicine. The Shen Lab is also a member of the Tumor Biology and Microenvironment Program of the Barbara Ann Karmanos Cancer Institute (KCI) - a National Cancer Institute (NCI) designated comprehensive cancer center. Supported by the State-of-the-art facilities such as proteomics, genomics, flow cytometry, and imaging cores at the Wayne State University and KCI, the Shen Lab aims to understand the mechanisms underlying cancer metastasis and treatment resistance by focusing on tumor microenvironment (TME). The Lab is also trying to develop novel TME remodeling therapeutic strategies to potentially reduce cancer mortality by using multiple animal systems, including Genetically Engineered Mouse Models (GEMMs), patient-derived xenograft (PDX), multiple experimental metastases models, and syngeneic tumor models. 代表文章: Shen M., Wei Y., Kim H., Wan L., Jiang Y., Hang X., Raba M., Remiszewski S., Rowicki M., Zhang L., Lu X., Yuan M., Smith H., Zheng A., Lin H., Bertino J., Jin J., Xing Y., Shao Z., Kang Y. (2021) Therapeutic Targeting of the MTDH-SND1 Complex Suppresses Breast Cancer Progression and Metastasis. Nature Cancer. In press Shen M., Smith H., Wei Y., Jiang Y., Zhao S., Wang N., Rowicki M., Tang Y., Hang X., Wan L., Shao Z., Kang Y. (2021) Disruption of the MTDH-SND1 Complex Enhances Tumor Antigen Presentation and Sensitizes Metastatic Breast Cancer to Anti-PD-1 Therapy. Nature Cancer. In press. Shen M., Jiang YZ., Wei Y., Ell B., Sheng X., Esposito M., Kang J., Hang X., Zheng H., Rowicki M., Zhang L., Shih WJ., Celia-Terrassa T., Liu Y., Shao ZM., Crestea I., Kang Y. (2019) Tinagl1 Suppresses Triple-Negative Breast Cancer Progression and Metastasis by Simultaneously Inhibiting Integrin/FAK and EGFR Signaling. Cancer Cell. 35(1): 64-80. Shen M., Cai Y., Yan X., Yang Y., Zhou T. (2013) Centrosomal protein FOR20 is essential for S-phase progression by recruiting Plk1 to centrosomes. Cell Research 23:1284-1295 |
» 搶金幣啦!回帖就可以得到:
+1/180
+1/84
+2/66
+1/41
+2/40
+1/32
+1/21
+1/20
+1/16
+1/10
+1/9
+1/8
+1/6
+1/5
+1/5
+1/5
+1/4
+1/4
+1/2
+1/1



| 24 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 復(fù)試調(diào)劑 +3 | Copy267 2026-03-10 | 3/150 |
|
|---|---|---|---|---|
|
[考研] 283求調(diào)劑 +3 | 小樓。 2026-03-12 | 6/300 |
|
|
[考研] 化工學(xué)碩306求調(diào)劑 +7 | 42838695 2026-03-12 | 7/350 |
|
|
[考研] 271求調(diào)劑 +7 | 生如夏花… 2026-03-11 | 7/350 |
|
|
[考研] 0856化工原理 +5 | z2839474511 2026-03-10 | 5/250 |
|
|
[考研] 求調(diào)劑 +5 | yfihxh 2026-03-09 | 5/250 |
|
|
[考研] 泣血叩求調(diào)劑恩,愿以丹心報師恩 +5 | Iuruoh 2026-03-11 | 5/250 |
|
|
[基金申請] 提交后的基金本子,已讓學(xué)校撤回了,可否換口子提交 +3 | dut_pfx 2026-03-10 | 3/150 |
|
|
[考研] 265求調(diào)劑 +8 | 小木蟲085600 2026-03-09 | 11/550 |
|
|
[考研] 收調(diào)劑 +7 | 調(diào)劑的考研學(xué)生 2026-03-10 | 7/350 |
|
|
[考研] 0817學(xué)碩華東區(qū)求調(diào)劑 +3 | 30660438 2026-03-08 | 3/150 |
|
|
[考研] 0703化學(xué)調(diào)劑 +3 | 三dd. 2026-03-10 | 3/150 |
|
|
[考研] 一志愿湖師大化學(xué)289求調(diào)劑 +5 | XMCMM3.14159 2026-03-10 | 5/250 |
|
|
[考研] 物理學(xué)求調(diào)劑 +4 | sx宋 2026-03-05 | 4/200 |
|
|
[基金申請] 面上項目還需要AI說明嗎? +3 | liyundong 2026-03-08 | 3/150 |
|
|
[考研] 數(shù)二英二309分請求調(diào)劑 +3 | dtdxzxx 2026-03-09 | 4/200 |
|
|
[考研] 一志愿山東大學(xué),總分327,英語二79,有論文,有競賽,已過四六級 +3 | 木木目目1 2026-03-09 | 3/150 |
|
|
[考研] 320求調(diào)劑 +4 | 魏zy 2026-03-08 | 4/200 |
|
|
[考研]
|
Sixuan wang 2026-03-06 | 7/350 |
|
|
[考研] 復(fù)試調(diào)劑 +5 | 呼呼?~+123456 2026-03-05 | 5/250 |
|